Short answer
MBX Biosciences, Inc. (MBX) filed its fiscal 2025 10-K annual report with the SEC on Mar 12, 2026.
- Top risk flagged: FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
FY2025 key financial metrics · XBRL
- Net income
- −$87M
- −40.5% YoY
- EPS (diluted)
- −$2.38
- +59.1% YoY
- ROE
- -23.6%
- +0.5 pp YoY
- Operating cash flow
- −$80M
- −46.2% YoY
Source: XBRL data from the MBX Biosciences, Inc. (MBX) FY2025 10-K on SEC EDGAR. USD.
MBX Biosciences, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Clinical-stage biopharma developing novel precision peptide therapies for endocrine and metabolic disorders via proprietary PEP™ platform
- New emphasis on once-weekly canvuparatide for chronic hypoparathyroidism with positive Phase 2 data; Phase 3 trial to start Q3 2026
- Strategic focus broadened with obesity portfolio including MBX 4291, a potential once-monthly GLP-1/GIP co-agonist advancing through Phase 1 and planned multiple ascending doses study in 2026
- Notable metric: Phase 2 trial of canvuparatide enrolled 64 HP patients with 63% responder rate at 12 weeks vs 31% placebo (p=0.042)
- Unique to 2026 filing: First detailed presentation of canvuparatide’s programmable prodrug and fatty acylation dual technology enabling continuous, infusion-like peptide exposure with low peak-to-trough ratio
Management Discussion & Analysis
- Net loss $87.0M in 2025 vs $61.9M in 2024; operating expenses rose $29.9M to $98.1M
- R&D expenses $79.2M (29.7% increase) driven by canvuparatide ($37.2M, up $15.6M) and MBX 4291 ($12.7M, up $1.9M); imapextide decreased $7.4M
- G&A expenses $18.9M up from $10.8M due to higher professional fees and personnel costs
- Cash, cash equivalents and marketable securities $373.7M at 12/31/25 vs $262.1M at 12/31/24; IPO net proceeds $170.5M, September 2025 Offering net proceeds $187.4M, and $87.1M raised via open market sales in early 2026
- Guidance: existing cash expected to fund operations into 2029; Phase 3 trial initiation of canvuparatide in Q3 2026; key risks include need for substantial new funding and clinical/regulatory uncertainties
Risk Factors
- FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
- Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations
- Operational risk: reliance on third-party manufacturers for clinical and commercial supply with risk of inadequate supply or quality of product candidates
- Competition risk: facing competing technological and market developments that may reduce value of future product candidates
- Financial risk: accumulated deficit $224.5M with ongoing losses ($87.0M in 2025) and need for substantial financing to continue development and commercialization
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.